Click the button below to contact us or submit your feedback about this product.
ImmunoArrayᵀᴹ Alzheimer's Disease (AD) Associated Autoantibody Detection Service/Antigen Microarray (CAT#: NA-0726-FY7)
Alzheimer's Disease Associated Autoantibody Detection Service is an ultra-sensitive, high-throughput multiplexed antigen microarray platform engineered to decode the complex neuro-immunological landscape of Alzheimer's disease. Available in two flexible configurations, this platform immobilizes high-quality purified proteins onto an advanced 3D microchip matrix to optimally maintain their native three-dimensional conformations. Requiring a mere 5 μL sample volume to run 16 parallel samples per slide, the service achieves simultaneous dual-isotype (IgG/IgA) detection across a vast 1-65000 dynamic range. Backed by built-in Ig/anti-Ig normalization pairs, it serves as an indispensable discovery engine for mapping systemic immune dysregulation, identifying high-accuracy early biomarkers, and accelerating the development of targeted diagnostic models and therapeutics for cognitive impairment.
| Specifications | |
|---|---|
| Size | Standard microchip substrate layout (Standard glass slide format) |
| Throughput Level | High-throughput multi-sample parallel screening; 16 samples can be processed simultaneously per individual slide |
| Protein Count | Features the largest AD-related antigen collection to date, offering two commercial versions: V1: 20 distinct autoantigens V2: 40 distinct autoantigens (selected based on comprehensive peer-reviewed literature) |
| Proteome Coverage | Target-specific neurodegenerative and disease coverage (Capable of multiplexed profiling of over 120 autoantibodies per reaction well) |
| Full-Length Protein Ratio | High conformational fidelity (High-quality purified antigens are coated onto a 3D matrix to optimally preserve their native three-dimensional structures) |
| Expression System | Specialized eukaryotic and purified expression pipelines engineered to maintain structural accuracy and intact biological epitopes |
| Purification Method | Advanced affinity and high-purity antigen isolation |
| Arraying Technology | Precise automated deposition onto a proprietary three-dimensional (3D) microchip surface |
| Quality Control | Integrated internal Ig and anti-Ig control pairs within every array for rigorous data normalization and absolute quantification |
| Features | Unprecedented Multi-Marker Breadth: Boasts the most extensive antigen portfolio engineered for Alzheimer's disease research, empowering investigators to move beyond individual targets and screen composite "autoantibody fingerprints." High Multiplexing & Micro-Volume Screening: Replaces conventional single-plex ELISA setups by analyzing more than 120 distinct autoantibodies in parallel within a single well, requiring an ultra-low sample volume of just 5 μL of serum or alternative biofluids. Dual-Isotype Fluorescence Interrogation: Employs advanced dual-color fluorophore-conjugated secondary antibodies to independently read two distinct antibody classes (IgG and IgA) on the exact same array surface, preserving rare or limited clinical samples. Vast Analytical Dynamic Range: Provides superior signal detection capabilities ranging from 1 to 65000 Relative Fluorescence Units (RFU), supporting highly precise relative quantification and semi-quantitative profiling through standard curves. Unparalleled Versatility & Cost Efficiency: Features a flexible array matrix that combines diverse biomolecules (proteins, peptides, nucleic acids) to screen across multiple antibody subtypes, reducing operational overhead to less than 1/10 the cost of traditional ELISA kits. |
| Application Fields | Early Alzheimer's Detection & Diagnosis: Uncovering subtle immunopathological changes and tracing specific autoantibodies (e.g., targeting Amyloid-beta and tau proteins) that manifest long before visible clinical symptoms or cognitive decline emerge. Disease Progression & Resilience Monitoring: Constructing multi-parameter diagnostic and prognostic models to monitor neuro-inflammatory pathways, distinguish cognitive resilience from active decline, and evaluate risks through longitudinal biofluid fingerprints. Mechanistic Neuro-Immunology Research: Investigating the dual roles of AD-related autoantibodies, mapping whether specific clones exert a protective effect (clearing harmful protein aggregates) or a pathogenic effect (triggering inflammation and neuron loss). Broad Neuro-Disorder & Vaccine Profiling: Profiling dense autoantibody cross-talk driving cerebral dysfunction, psychiatric disorders, systemic lupus erythematosus (SLE), and tracing potential autoimmune-mediated side effects following viral infections or vaccinations. Therapeutic Stratification & Clinical Trials: Providing highly reliable multi-marker tracking platforms to stratify patient cohorts, evaluate candidate drug efficacy, and monitor target-engagement or neurotoxicities during clinical trials. |
DatasheetFor Research Use Only | Not For Clinical Use
Related products
- ImmunoArrayᵀᴹ Autoantibody Detection Microarray Service (CAT#: NA-0726-FY12)
- ImmunoArrayᵀᴹ Ganglioside and Phospholipid Antigen Microarray Service (CAT#: NA-0726-FY11)
- ImmunoArrayᵀᴹ Paraneoplastic Neurological Syndrome (PNS) & Autoimmune Encephalitis (AE) Associated Autoantibody Detection Service/Antigen Microarray (CAT#: NA-0726-FY6)
- ImmunoArrayᵀᴹ Neuroimmune-Related Autoantibody Detection Service (CAT#: NA-0726-FY15)
- ImmunoArrayᵀᴹ Extractable Nuclear Antigen (ENA) and Antinuclear Antibody (ANA) Detection Service (32 Antigens) (CAT#: NA-0726-FY25)
- ImmunoArrayᵀᴹ Cancer and Tumor-Related Autoantibody Detection Service (CAT#: NA-0726-FY16)
- ImmunoArrayᵀᴹ Glycosaminoglycan (GAG) Microarray (CAT#: NA-0726-FY37)
- ImmunoArrayᵀᴹ Small Molecule Drug Microarray (CAT#: NA-0726-FY3)
Services:
Resource:
Applications:
Online Inquiry